Background Genome-wide association studies (GWAS) for Parkinson's disease have linked two loci (MAPT and SNCA) to risk of Parkinson's disease. We aimed to identify novel risk loci for Parkinson's disease.
Introduction
Parkinson's disease was long thought to be a non-genetic disease. Recent advances in genotyping have enabled large-scale assessment of genetic risk factors associated with Parkinson's disease. MAPT and SNCA 1-5 have consistently shown associations in genome-wide association studies (GWAS). BST1, LRRK2, GAK, and HLA-DRB5 1-3,5-7 have been implicated in some studies but these associations have not been defi nitively confi rmed.
Although an exciting next step in the genetic study of human disease will be the use of exome or genome sequencing in adequately powered large-scale populationbased studies, this method is cost prohibitive at present. 8 A compromise between array-based and sequence-based methods is the use of freely available sequence-based resources from the 1000 Genomes Project, which allows imputation of a large number of variants into existing genotyping studies.
We did a meta-analysis of Parkinson's disease GWAS to investigate the associations of previously identifi ed loci and identify novel risk loci for Parkinson's disease.
Methods

Study design
Investigators representing four published GWAS [1] [2] [3] 9 formed a consortium with the predetermined goal to discover new loci associated with Parkinson's disease by a prospective meta-analysis of imputed sequence variants (discovery stage). We identifi ed one additional dataset from the database of genotypes and phenotypes. 5, 10 A secondary requirement for inclusion of a dataset in this study was the ability to use custom-built ImmunoChip arrays to do replication analyses in independent sample series (replication stage). The fi ve included datasets were from the USA National Institute on Aging, UK, Germany, France, and the USA database of genotypes and phenotypes. [1] [2] [3] 5, 9, 11 We aimed to assess the biological consequences of risk variants identifi ed in our study by examining the association between these alleles and both gene expression and DNA methylation. Our primary interest in these single nucleotide polymorphism (SNP)-based analyses was to investigate every locus associated with Parkinson's disease and to test whether the diseaserelated SNPs were associated with DNA methylation or gene expression levels. Further, we wanted to test whether the most strongly disease-associated SNPs were also the most strongly associated quantitative trait locus SNPs.
Data imputation and statistical analysis
After individual sample collection and study-specifi c quality control (webappendix pp 1-7), we used a Markov Chain based haplotyper (MACH; version 1.0.16) on every dataset to impute genotypes for all participants of European ancestry with haplotypes derived from initial low coverage sequencing of 112 European ancestry samples in the 1000 Genomes Project (as of August, 2009). 12, 13 For all datasets, data were imputed by a two-stage design. The fi rst stage generated error and crossover maps as parameter estimates for imputation on a random subset of 200 samples per study over 100 iterations of the initial statistical model. We used these parameter estimates to generate maximum likelihood estimates of allele numbers per SNP on the basis of reference haplotypes for the datasets during the second stage of the imputation. SNPs with RSQR quality estimates of less than 0·30 as indicated by MACH were excluded from analyses of the datasets, because imputed genotypes below this threshold are probably of poor quality.
We did genome-wide dataset analyses at every site with MACH2DAT. 12 We used non-integer allele numbers as a primary predictor of Parkinson's disease in logistic regression models to account for imputation uncertainty.
Webappendix pp 1-7 shows specifi c details of analyses of the datasets. Summary statistics from genome-wide association analyses of every dataset were included in the meta-analyses. For every dataset, we used basic covariates of component vectors 1 and 2 from either principal components or multidimensional scaling analyses of the case-control cohorts to identify random genomic diff erences between genotyped data from cases and controls in the discovery phase, which were used to adjust statistical models for covariates accounting for possible population substructure. This adjustment was not done in analyses of the UK dataset in the discovery phase of analyses.
For the replication step, we included the SNPs that passed genome-wide signifi cance (fi xed eff ects p<1×10 -⁵) and quality control on a custom ImmunoChip array (Illumina, San Diego, CA, USA) in collaboration with the Sanger Institute (Hinxton, UK). Additionally, we analysed two GWAS (from the Netherlands and Iceland) after the meta-analysis and included these in the replication stage by the same imputation procedure. These data were provided by consortium members who provided the GWAS data after the initial discovery phase. We included a quality control step in the replication analyses that removed SNPs with inconsistent results across the datasets (I²>75%). 14, 15 Webappendix pp 4-8 shows detailed descriptions of the replication analyses that were done in the fi ve ImmunoChip replication cohorts (USA, UK, Netherlands, Germany, and France) and two in-silico GWAS datasets (Iceland and Netherlands).
We did fi xed-eff ects inverse variance-weighted metaanalyses with meta-analysis helper (METAL), 16, 17 with the standard errors of the β coeffi cients scaled by the square root of study-specifi c genomic infl ation factor estimates before combining the summary statistics across datasets. We calculated genomic control for both individual datasets and the entire meta-analysis for quality control. Genomic control is often estimated as the deviance of the median test statistic distribution from the expected null; genomic infl ation factors less than 1·05 are the general standard in GWAS. 18 We used fi xed-eff ects metaanalyses as the primary method of discovery and R (version 2.11) to do a secondary random-eff ects metaanalysis for every SNP. 19 This second analysis is useful to estimate the possible eff ect of study heterogeneity on results and to qualitatively infer the eff ect of study heterogeneity on replication success and generalisability for similar sample series. We calculated χ² tests for heterogeneity (Cochran's Q) with METAL and we generated I² estimates with R. Meta-analyses and estimates of study heterogeneity were re-run with PLINK as a quality control measure.
We calculated risk-profi le estimates on the basis of cumulative load of risk alleles for loci identifi ed in the discovery phase, weighted by the discovery phase eff ect estimates (log odds ratio ). This profi le model was applied to the ImmunoChip genotyped replication cohorts, and the eff ects were combined across cohorts by inverse variance weighting.
Population-attributable risk was estimated for the specifi c genetic contribution to disease of the risk loci NIA=National Institute on Aging. NA=not available. dbGAP=database of genotypes and phenotypes. *Adjusted for component vectors 1 and 2 from multidimensional scaling analyses of the study population. †Passed quality control in at least two of the included datasets; ‡Summary statistics scaled by study-specifi c genomic infl ation factors before meta-analysis. identifi ed. In broad terms, it estimates the decrease in cases of a particular disease within a population that would occur if the risk factor were removed from that population. Eff ect sizes and minor allele frequencies were calculated from joint estimates from the discovery and replication phases combined, to lessen the overestimation caused by the so-called winner's curse-a form of ascertainment bias that often occurs in two-stage GWAS wherein natural genetic variation contributes to a slight overestimation of eff ect sizes in the discovery phase. 20 Joint estimates were also used because of their large sample size, which should generate more accurate eff ect estimates.
DNA methylation values at sites close to the risk variants and the expression of genes within the risk loci were treated as quantitative traits, and we assessed whether the alleles of SNPs across the risk loci were associated with either, denoting a quantitative trait locus. Webappendix pp 10-13 and a previous study 21 provide more detail about the methods used to map quantitative trait loci. Briefl y, we used dense genotype data generated in up to 350 people who had donated brain tissue and were neurologically healthy at the time of death. DNA methylation and transcript expression were assessed in frozen tissue from both frontal cortex and cerebellum samples of every brain. We tested the association between any typed polymorphism and any assayed DNA methylation site or transcript. All SNPs within 1 mb from the SNPs with the smallest p values per locus with fi xedeff ects p values less than 1×10 -⁵ were investigated as candidate loci that aff ect the expression and methylation values of proximal mRNA transcript probes and CpG methylation sites. With the minor allele as a reference for directionality, we used linear models to quantify the relation between quantitative trait loci and risk eff ect for all the loci that contained signifi cant quantitative trait locus associations. We used linkage-adjusted Bonferroni correction for signifi cance (webappendix pp 11-13).
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All members of the writing group had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
The discovery phase included 5333 case and 12 019 control samples, with genotyped and imputed data at 7 689 524 SNPs (table 1; fi gure 1). 7053 case and 9007 control samples were included in analyses in the replication stage. Results of tests across the software packages METAL, R, and PLINK diff ered only slightly (data not shown).
We identifi ed 11 loci that surpassed the threshold for genome-wide signifi cance (p<5×10 -⁸; table 2). 18 One locus on chromosome 17 from 18 601 523 to 18 602 998 bp that contained six SNPs associated with Parkinson's disease in the UK cohort was not included because p values were not less than 0·1 in any other cohort and I² was greater than 75%. For simplicity, we have focussed only on the most signifi cant SNP per locus that met these criteria, and its nearest gene or genes. However, we do recognise that the most proximal gene is not necessarily the gene functionally aff ected by risk alleles and that GWAS identify loci rather than specifi c genes. Webappendix pp 15-31 provides more detailed results for every region.
We confi rmed the Parkinson's disease associations at the SNCA and MAPT loci 1-5 and at BST1, LRRK2, GAK, and HLA-DRB5 (table 2) . 1,-3,5-7 Additionally, we detected evidence of associations at fi ve new loci (the closest gene to the top SNP at every loci is ACMSD, STK39, MCCC1/LAMP3, SYT11, and CCDC62/HIP1R). However, two of these loci (ACMSD and CCDC62/HIP1R) showed moderate evidence of heterogeneity across populations. Webappendix pp 7-8 provides further details about the replication phase of analysis. All fi ve novel loci passed a Bonferroni threshold of p<0·0045 (correcting for the 11 SNPs tested in the replication phase) for association in the replication phase.
The SNP at the SYT11 locus is about 650 kb from the known Parkinson's disease risk factor gene GBA and its pseudogene, in a region of the genome with low recombination. 22 To test whether this proximity might contribute to the possible co-segregation of risk alleles at the SYT11 locus and GBA risk mutations we analysed data from a subset of patients with Parkinson's disease Chromosome who were included in the discovery phase analysis and who were from the USA, France, and Germany, in whom carriers of the GBA mutation have been identifi ed. The results of this analysis suggested that the signal at the SYT11 locus is independent of GBA mutations (webappendix pp 9-10 and pp [32] [33] . Similarly, we did an analysis that controlled for the known common LRRK2 mutation G2019S in the replication phase, and showed that the association detected in the meta-analysis close to LRRK2 might be caused by variation independent of this mutation (webappendix pp 9-10 and pp 32-33). Table 2 shows the combined population-attributable risk estimates. The combined estimate across all 11 identifi ed loci was 60·3% (95% CI 43·7-69·3). For the MAPT and SNCA loci alone it was 25·6% (18·7-28·9), which was higher than the previous estimate of about 20%. 2 The additional loci identifi ed in this study (ACMSD, STK39, MCCC1/LAMP3, and CCDC62/HIP1R) had a combined estimate of 46·7% (30·7-56·8).
The odds ratio was 2·5 times higher in the highest quintile of disease risk than in the lowest quintile of disease risk (table 3) . The c index from receiver operator curves in the pooled cohorts was 0·63.
We identifi ed quantitative trait associations at 18 969 SNPs spread across fi ve of the identifi ed Parkinson's disease risk loci (summarised in fi gure 2, with complete results available from the authors upon request). The MAPT locus had many such associations, with 95·9% of all associations detected across all tissues and arrays in this region. For the MAPT locus, risk estimates were positively associated with quantitative trait locus eff ects, leading to increased gene expression (cerebellum r² 0·1366; frontal cortex r² 0·8042; both tissues p<2×10 -¹⁶). We noted the opposite eff ect in the methylation quantitative trait loci at MAPT, with minor Combined analyses showed low heterogeneity of eff ect (Cochran's Q p>0·01). AUC=area under curve, indicated by the c index from receiver operator curves. OR=odds ratio. Two SNPs in the ACMSD locus showed substantial associations, with expression levels in cerebellar tissues denoted by a proximal expression probe against the transcript MCM6, whose transcription start site is more than 750 kb from either associated SNP; the minor alleles at this pair of SNPs are associated with increased risk of Parkinson's disease and decreased gene expression. In samples from the frontal cortex, DNA methylation values at one CpG site within FGFRL1 were associated with 27 proximal SNPs in the GAK region (>20 kb from the nearest SNP associated with Parkinson's disease), and all eff ect estimates suggested risk of Parkinson's disease and increased methylation (r² 0·9897, p<2×10 -¹⁶). The HLA-DRB5 region contained 729 signifi cant quantitative trait locus associations in the frontal and cerebellar tissue samples. For HLA-DRB5, we recorded an overall result similar to that identifi ed at MAPT, with minor alleles associated with risk eff ects and with decreased DNA methylation (cerebellum r² 0·4037, p=9·67×10 -⁵; frontal cortex r² 0·4977, p<2×10 -¹⁶). In addition to probes within HLA-DRB5, methylation quantitative trait locus associations were detected within probes tagging CpG sites in BTNL2, HLA-DQB2, and SLC44A4. One CpG probe in the cerebellum samples was associated with 18 SNPs in the CCDC62/HIP1R region. We noted a relation between risk alleles and DNA methylation at a CpG site within GPR109B, for which increased risk estimates were closely associated with more negative methylation eff ects (cerebellum r² 0·4977, p<2×10 -¹⁶). Both the LRRK2 and SNCA genes play a part in Parkinson's disease; thus, we examined these loci further for potential quantitative trait loci. Detection of LRRK2 with the array-based method showed expression that was too low to do an accurate analysis. However, we identifi ed quantitative trait loci at the SNCA locus, where risk alleles were associated with increased SNCA expression. Although evidence suggests a link between SNCA expression and disease risk, 23 the level of signifi cance for this locus was not signifi cant (p=1×10 -⁴) with the threshold for signifi cance that we set (p<3·55×10 -⁵).
Discussion
SNCA, MAPT, and HLA-DRB5 have been confi rmed as risk loci for Parkinson's disease by previous GWAS 1- 7, 9 and by our meta-analysis. We have also shown that, although previous GWAS were individually underpowered to prove the associations between the BST1, LRRK2, and GAK loci and Parkinson's disease, our metaanalysis and replication analysis identifi ed an association at these loci (panel).
1-3,5,6,9
GWAS investigate loci that often contain several genes and we should be mindful not to ascribe disease risk to any one gene within this locus in the absence of further biological evidence. However, the novel loci detected include biologically plausible candidate for Parkinson's CCDC62/HIP1R effect concordance disease risk. ACMSD is associated with picolinic and quinolinic acid homoeostasis and is a possible therapeutic target for several disorders that aff ect the CNS. 24 The locus identifi ed near STK39 has been associated with autism, hypertension, and infl ammatory status, [25] [26] [27] although there have been no reports of this locus contributing to neurodegenerative phenotypes. The LAMP3 locus might partly cause modulation of neuronal and neurosecretory function in PC12 cell lines. 28 HLA-DRB5 is associated with multiple sclerosis, immunocompetence, and histocompatibility. [29] [30] [31] The association with Parkinson's disease at HLA-DRB5 supports the theory that infl ammatory factors are associated with the pathogenesis of Parkinson's disease. 32 The protein product of HIP1R is functionally involved in intrinsic cell-death pathways and interacted with huntingtin to modulate polyglutamine-induced neuronal dysfunction in transgenic worm and mouse models. 33 Finally, the association detected at the SYT11 locus includes a gene that has been investigated previously in a negative mutation screening study in 393 patients with familial or sporadic Parkinson's disease 34 and in a cell biology study that showed an interaction between the protein products of SYT11 and PARK2 in patients with Parkinson's disease. 35 The association between genetic variability at the LRRK2 locus and Parkinson's disease is mechanistically interesting because data suggest that this association is a result of variability outside the common G2019S mutation, which raises the possibility that splicing or expression of wild-type LRRK2 might be pathologically important. If this suggestion is correct, the role of LRRK2 in Parkinson's disease might relate to an exaggeration of its normal function rather than some gain of abnormal function.
Understanding of the pathobiologically relevant eff ect of the identifi ed risk variants in Parkinson's disease is challenging. However, we associated changes in expression and DNA methylation with risk alleles at fi ve of the identifi ed loci. This work has many caveats, not least of which is that it is associative and does not imply causality. However, these data do serve as a launching point for further investigation into the biological basis of Parkinson's disease.
The absence of predictive capacity in the risk-profi le estimates suggests that common genetic variability at these loci, the small risk estimates per locus in this metaanalysis (and GWAS-based studies in general), and the inability to include putative functional variants per locus, do not allow clinically relevant predictive power to be quantifi ed. Additionally, no environmental factors were included in risk profi ling or population-attributable risk estimates, which might have led to some overestimation of the genetic risk of Parkinson's disease, because its cause is probably not entirely genetic.
Assumptions are unavoidable when modelling population-attributable risk with data from GWAS. Thus, we have probably overestimated the genetic component of Parkinson's disease risk on the basis of these loci alone because bias inherent in using a case-control study will slightly skew the frequency of risk alleles higher. However, this calculation did allow us to rank the contribution of every locus to the genetic cause of Parkinson's disease, and to estimate the possible decrease in the future incidence of Parkinson's disease achieved by preventative treatments targeted at genetic causes. Risk-profi le modelling provides a conservative estimate of genetic risk and has moderate predictive power. The identifi cation of additional common and rare risk variants for Parkinson's disease will probably revise our estimate of the genetic component of disease upward. 1-3,9,11 For those studies outside the existing framework of the consortium, we used all studies that included more than 300 000 single nucleotide polymorphisms and for which the underlying genetic data were available for download. This resulted in one additional dataset being added to the meta-analysis.
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Interpretation
Up to now, to our knowledge this study is the largest genetic analysis of Parkinson's disease undertaken and has confi rmed the associations at six previously implicated loci and also identifi ed fi ve new loci. This study provides evidence that common genetic variation plays an important part in the cause of Parkinson's disease. We have confi rmed a strong genetic component to Parkinson's disease, which, until recently, was thought to be completely caused by environmental factors. The genomic loci described show the rapid pace of growth in the specialty of genome-wide association studies of complex disease, and the future predictive use of genes identifi ed in such studies.
